We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Drug Resistant Bacterial Strains Impact Infectious Disease Diagnostic Segment

By LabMedica International staff writers
Posted on 02 Sep 2009
The most substantial growth in the US $8.4 billion market for infectious disease diagnostics will be in molecular testing. More...
The expanding population of drug resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and multidrug resistant Mycobacterium tuberculosis (TB) will vindicate the use of nucleic acid-based tests (NAT).

The two traditional methods, culture-based assays and immunoassays, are becoming increasingly inadequate for infectious disease testing. Emergence of drug-resistant bacterial strains means that immunoassays have no analytical potential. Culture-based assays for bacterial susceptibility/sensitivity, although inexpensive, are slow and often difficult.

Laboratories are still largely equipped with immunoassay instrumentation, but not all have access to a thermal cycler or the expertise to perform a molecular MRSA test. According to a report by life science market research company Kalorama Information, (New York, NY, USA) replacement of current assays with molecular-based tests will be slow because of the recession. Therefore, both culture-based assays and immunoassays will remain in use for infectious disease tests that do not require rapid turn-around or are otherwise difficult to perform. The cost of nuclear acid-based NAT assays, which are not usually analyzed outside the hospital laboratory, is high at around $25-$35, while selective media cost about $5 a plate.

"Relevancy is established through significantly improved efficacy and not marginal improvement,” said Bruce Carlson, publisher of Kalorama Information. "NAT testing can be put to many uses, but what will get it into more labs is its role in determining the genetic differences that make a bacterial strain […..] drug resistant, with results in 2-4 hours.”

NAT testing will allow physicians to rapidly select combination therapeutics for infections caused by resistant organisms. In viral applications, for example in human immunodeficiency virus (HIV) infection, NAT testing successfully detected drug resistance that developed in response to therapy.

Related Links:
Kalorama Information


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.